N N Kammer1, E Coppenrath2, K M Treitl2, H Kooijman3, O Dietrich4, T Saam2. 1. Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Nussbaumstr. 20, 80336, Munich, Germany. nora.kammer@med.lmu.de. 2. Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Nussbaumstr. 20, 80336, Munich, Germany. 3. Philips Healthcare, Luebeckertordamm 5, 20099, Hamburg, Germany. 4. Josef Lissner Laboratory for Biomedical Imaging, Institute for Clinical Radiology, Ludwig-Maximilians-University Hospital Munich, Marchioninistr 15, 81377, Munich, Germany.
Abstract
OBJECTIVES: To compare a modified T1-weighted 3D TSE black-blood sequence with sub-millimetre resolution (T1-mVISTA) with a magnetization-prepared rapid gradient echo (MP-RAGE) sequence for the diagnosis of cerebral malignomas. METHODS: Forty-six patients with known or suspected intracranial tumours and 15 control patients were included in this retrospective study. All patients underwent T1-mVISTA (0.75-mm isotropic resolution, 4:43 min) and MP-RAGE (0.8-mm isotropic resolution, 4:46 minutes) at 3-Tesla in random order after application of contrast agent. Two experienced radiologists determined the number of lesions. Maximum diameter, diagnostic confidence (DC), visual assessment of contrast enhancement (VCE) and CNRlesion/parenchyma were assessed for each lesion. RESULTS: Significantly more lesions were detected with T1-mVISTA compared to the MP-RAGE (61 vs. 36; p < 0.05). Further, DC and VCE was rated significantly higher in the T1-mVISTA (p < 0.05 and p < 0.001). Mean CNRlesion/parenchyma was twofold higher for T1-mVISTA (24.2 ± 17.5 vs. 12.7 ± 11.5, p < 0.001). The 25 lesions detected only in T1-mVISTA were significantly smaller than those detected in both sequences (4.3 ± 3.7 mm vs. 11.3 ± 10.7 mm; p < 0.01). CONCLUSIONS: T1-mVISTA increases the contrast of lesions significantly compared to MP-RAGE and might therefore improve detection rates of small lesions in early stages of disease. KEY POINTS: • T1-mVISTA leads to significantly higher contrast-to-noise ratios of cerebral malignomas. • T1-mVISTA detects significantly more metastatic lesions compared to 3D-MPRAGE. • Lesions detected only by T1-mVISTA are smaller than those detected in both sequences. • Diagnostic confidence is significantly higher for lesions detected by T1-mVISTA. • Application of T1-mVISTA might be of high relevance in early stages of disease.
OBJECTIVES: To compare a modified T1-weighted 3D TSE black-blood sequence with sub-millimetre resolution (T1-mVISTA) with a magnetization-prepared rapid gradient echo (MP-RAGE) sequence for the diagnosis of cerebral malignomas. METHODS: Forty-six patients with known or suspected intracranial tumours and 15 control patients were included in this retrospective study. All patients underwent T1-mVISTA (0.75-mm isotropic resolution, 4:43 min) and MP-RAGE (0.8-mm isotropic resolution, 4:46 minutes) at 3-Tesla in random order after application of contrast agent. Two experienced radiologists determined the number of lesions. Maximum diameter, diagnostic confidence (DC), visual assessment of contrast enhancement (VCE) and CNRlesion/parenchyma were assessed for each lesion. RESULTS: Significantly more lesions were detected with T1-mVISTA compared to the MP-RAGE (61 vs. 36; p < 0.05). Further, DC and VCE was rated significantly higher in the T1-mVISTA (p < 0.05 and p < 0.001). Mean CNRlesion/parenchyma was twofold higher for T1-mVISTA (24.2 ± 17.5 vs. 12.7 ± 11.5, p < 0.001). The 25 lesions detected only in T1-mVISTA were significantly smaller than those detected in both sequences (4.3 ± 3.7 mm vs. 11.3 ± 10.7 mm; p < 0.01). CONCLUSIONS: T1-mVISTA increases the contrast of lesions significantly compared to MP-RAGE and might therefore improve detection rates of small lesions in early stages of disease. KEY POINTS: • T1-mVISTA leads to significantly higher contrast-to-noise ratios of cerebral malignomas. • T1-mVISTA detects significantly more metastatic lesions compared to 3D-MPRAGE. • Lesions detected only by T1-mVISTA are smaller than those detected in both sequences. • Diagnostic confidence is significantly higher for lesions detected by T1-mVISTA. • Application of T1-mVISTA might be of high relevance in early stages of disease.
Authors: Olaf Dietrich; José G Raya; Scott B Reeder; Maximilian F Reiser; Stefan O Schoenberg Journal: J Magn Reson Imaging Date: 2007-08 Impact factor: 4.813
Authors: Ye Qiao; David A Steinman; Qin Qin; Maryam Etesami; Michael Schär; Brad C Astor; Bruce A Wasserman Journal: J Magn Reson Imaging Date: 2011-07 Impact factor: 4.813
Authors: Keigo Kawaji; Thanh D Nguyen; Zhitong Zou; Beatriu Reig; Priscilla A Winchester; Andrew Shih; Pascal Spincemaille; Martin R Prince; Yi Wang Journal: J Magn Reson Imaging Date: 2011-07-18 Impact factor: 4.813
Authors: E Nagao; T Yoshiura; A Hiwatashi; M Obara; K Yamashita; H Kamano; Y Takayama; K Kobayashi; H Honda Journal: AJNR Am J Neuroradiol Date: 2011-02-03 Impact factor: 3.825
Authors: Miriam Reichert; John N Morelli; Val M Runge; Ai Tao; Ruediger von Ritschl; Andreas von Ritschl; Abraham Padua; James E Dix; Michael J Marra; Stefan O Schoenberg; Ulrike I Attenberger Journal: Invest Radiol Date: 2013-01 Impact factor: 6.016
Authors: Tobias Saam; Jose G Raya; Clemens C Cyran; Katja Bochmann; Georgios Meimarakis; Olaf Dietrich; Dirk A Clevert; Ute Frey; Chun Yuan; Thomas S Hatsukami; Abe Werf; Maximilian F Reiser; Konstantin Nikolaou Journal: J Cardiovasc Magn Reson Date: 2009-10-27 Impact factor: 5.364
Authors: L Danieli; G C Riccitelli; D Distefano; E Prodi; E Ventura; A Cianfoni; A Kaelin-Lang; M Reinert; E Pravatà Journal: AJNR Am J Neuroradiol Date: 2019-06-20 Impact factor: 3.825
Authors: Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan Journal: Childs Nerv Syst Date: 2021-05-10 Impact factor: 1.475
Authors: Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300